Background Although widely used, thiopurine drugs have a narrow therapeutic index and treatment can result in life-threatening toxicity, the basis being pharmacogenetic variation in thiopurine metabolism by thiopurine S-methyltransferase (TPMT). We recently developed a modified phenotyping assay to determine TPMT activity in red blood cells. Here we describe improvements to the method and establish reference intervals in a large prospective study.
Introduction
Thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-thioguanine are used in the treatment of autoimmune diseases, acute lymphoblastic leukaemia and to prevent post-transplant organ rejection. 1 Toxic side-e¡ects of thiopurine drugs include pancreatitis, hepatotoxicity, allergic reactions and myelosuppression. 2 Azathioprine and 6-mercaptopurine are prodrugs, their therapeutic e¡ects relating to intracellular conversion to thiopurine nucleotides. 1 Metabolic pathways for azathioprine, 6-mercaptopurine and 6thioguanine are shown in Fig. 1 . Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs and is an important pathway in their metabolism. 3 In 1980, it was demonstrated that the distribution of TPMT activity in red blood cells (RBC) in Caucasians is trimodal, with 0.3% of the population having no detectable enzyme activity, 10% intermediate activity and 90% high activity. Patients with absent TPMT activity are at most risk of severe myelosuppression, whilst patients with intermediate TPMT activity are prone to toxicity. 4 The measurement of TPMT activity at the start of thiopurine therapy has a role in establishing which patients are at risk of thiopurine-induced toxicity, and for directing appropriate therapy. With knowledge of TPMT activity status, even patients that have no TPMT activity have been successfully treated. 5 
Screening
Original Article patients' RBC TPMT activity prior to commencing thiopurine drugs is therefore potentially useful as it enables the patient to be treated correctly at the outset. TPMT activity in RBCs has been shown to re£ect the level of activity in other tissues. 3 This approach promises to reduce the incidence of signi¢cant toxicity and to avoid the need for more expensive alternative treatments.
There are many published methods for measuring TPMT activity. These incubate either mercaptopurine or thioguanine with the methyl donor S-adenosyl-Lmethionine (SAM) and RBC lysate to produce the methylated products 6-methylmercaptopurine (6-MMP) or 6-methylthioguanine (6-MTG). The products of the TPMT-catalysed reaction can be detected in a number of di¡erent ways, including radiochemical assay 1 and high-performance liquid chromatography (HPLC) with absorbance 6 or £uorescence detection. 7^9 Currently, work is ongoing to look at massspectrometric detection. Traditional analytical approaches often involve complex steps and are labour-intensive. The associated high analytical cost has hindered uptake of the test in clinical practice, with clinical protocols often relying on the changes in white cell counts to identify patients who are being overtreated.
We have previously published an HPLC method using 6-thioguanine as substrate for the determination of TPMT activity in RBC. 7 As 6-thioguanine metabolism is not dependent on the action of xanthine oxidase, there is no need to add the enzyme inhibitor allopurinol. The use of heat to stop the TPMT reaction and prepare the sample prior to HPLC analysis removes the need for solvent extraction. All steps are undertaken in a sealed tube; this reduces sample handling, imprecision and the possibility of laboratory error. This method is designed for use in a referral laboratory, where the assay can be applied to large numbers of clinical samples.
Here, we report modi¢cations to our original technique, including automation of lysate haemoglobin analysis and improved chromatography, resulting in a faster analysis time. We have used the new method to establish reference intervals for TPMT activity in a prospective study of 1000 outpatients, which is the ¢rst time that a study of this size has been reported.
Materials and methods

Study population and sample collection
Blood samples (4 mL collected in EDTA) were obtained over a 1-month period from 1000 random patients attending outpatient phlebotomy for routine tests. Ages ranged from16 to 96 years, with a mean age of 53 years; 469 of the subjects were men and 531 women. Patients who were younger than 16 years of age, those who were pregnant or who had taken thiopurine drugs within the last 6 months were excluded. Approval for this study was given by the West Birmingham Local Research Ethics Committee and informed patient consent obtained.
On the same day as collection, samples were centrifuged at 1400 g for 5 min and the serum and white cell layer removed. The RBC were washed in 2 mL of physiological saline, mixed by inversion and then centrifuged at 1400 g for 5 min. The saline was removed, and the washed cells stored at 7708C for a maximum of 4 weeks.
Lysate preparation and haemoglobin analysis
The frozen washed RBC were thawed, 0.25 mL was suspended in 1mL of phosphate bu¡er (0.02 mmol/L, pH 7.4) and mixed vigorously for 30 s to lyse the cells.
The haemoglobin content of the lysates (25 mL) was measured using an ILAB600 Clinical Chemistry System (Instrumentation Laboratory,Warrington, UK) with 200 mL of ADVIA 120 HGB reagent (Bayer, Berkshire, UK). The absorbance was measured at 546 nm after a 28 s incubation at 378C. For calibration, a standard curve was prepared from a 14 g/dL Hb 
Incubation and HPLC analysis
Enzyme incubation and HPLC analysis were performed as described previously, 7 with the following modi¢cations. An incubation mixture containing ¢nal concentrations of 600 mmol/L 6-thioguanine (GlaxoSmithKline, Uxbridge, UK) and 80 mmol/L SAM (Sigma-Aldrich, Poole, UK) in 0.1mol/L potassium phosphate bu¡er (pH 7.4) was aliquoted (0.5 mL) into 2 mL screw-top glass vials with caps (Chromacol, Welwyn Garden City, UK; cat. nos PN 2-SVW and PN 9-SC(B)-ST1) and stored at 7708C for up to 1 month. After pre-incubating the tubes, 200 mL of lysate was added to the vials and incubated for exactly1h at 378C. The enzyme reaction was stopped by heat inactivation at 858C for 10 min, which also deproteinizes the incubate. The vials were centrifuged at 1400 g for 5 min to provide a clear supernatant for injection. Sample blanks were prepared by stopping the reaction at time zero.
The linearity of the reaction was checked by studying the amount of product produced during a 120-min incubation. The same RBC lysate was set up in multiple reaction vials and duplicates were removed at set times up to 120 min of incubation.
HPLC analysis was performed using a Gynkotech Model 300 isocratic pump (Severn Analytical, Maccles¢eld, UK), a Chromsystems CLC 200 autosampler ¢tted with a 20-mL loop (Chromsystems, Munich, Germany) and a Hewlett Packard 1100 series £uorimeter (excitation 310 nm, emission 390 nm), driven by a CSW232 v1.4 chromatographic station (2002 DataApex Ltd, Prague, Czech Republic).
The stationary phase was a Kingsorb reversedphase column (C18, 75 mm64.6 mm, 3-mm particle size; Phenomenex, Maccles¢eld, UK) at ambient temperature, protected with a 4 mm63 mm guard column (SecurityGuard, Phenomenex). The mobile phase (£ow-rate 1.5 mL/min) was phosphate bu¡er (0.05 mol/L)-acetonitrile-tetrahydrofuran (89:7:4, v/v), ¢nal pH 6.2 after addition of organic solvents.
A single-point 0.44 nmol (80 ng) 6-MTG calibrant (Sigma-Aldrich) was used to standardize the assay. A standard blank (200 mL of 0.9 g/L NaCl) was included in each run to correct for non-enzymatic 6-MTG produced in the incubate. A quality control sample obtained from a healthy volunteer was stored as washed cells at 7708C and run each time the assay was performed.
Statistics and calculations
The data were analysed using MINITAB Statistical Software, version 13 (MINITAB Inc., Coventry, UK).
The amount of TPMT activity was calculated from 6-MTG peak height. The results are expressed in relation to lysate haemoglobin concentration (i.e. nmol 6-MTG per g Hb per h).
Results
The imprecision of the lysate haemoglobin method on the ILAB600 Clinical Chemistry System at a haemoglobin value of 3.5 g/dL were within-run coe⁄cient of variation (CV) 0.71% (n ¼15); between-run CV 1.2% (n ¼ 20).
The imprecision of the overall method was established using di¡erent batches of lysate prepared from the RBC of a volunteer. Results for within-batch and between-batch imprecision are presented in Table 1 . Using a preparation of lysed RBC stored at 7708C, we observed that TPMT activity is stable for at least 12 weeks.
The results for the linearity experiment are shown in Fig. 2 and demonstrate that there was su⁄cient substrate in the incubate to give a linear response over a period of 120 min.
The distribution of TPMT enzyme activity in the 1000 individuals is presented in Fig. 3 . Typical chromatograms for subjects with no activity and low, normal and high activity are shown in Fig. 4 . The retention time for 6-MTG was 1.7 min. All patients' sample blanks tested in this study were found to be free of interfering peaks at the retention time of 6-MTG.
The distribution of TPMT activity is consistent with previous studies. 1, 10, 11 TPMT activities ranged from 51 to 76 nmol 6-MTG per g Hb per h, with a mean and median activity of 33 and 33 nmol 6-MTG per g Hb per h, respectively. There was no signi¢cant di¡erence between the range, mean and median TPMT activities for men and women. For men (n ¼ 469), the mean and median TPMT activities were 34 and 34 nmol 6-MTG Ann Clin Biochem 2004; 41: 303-308 per g Hb per h, and for women (n ¼ 531),33 and 32 nmol 6-MTG g Hb h, respectively. Table 2 shows the reference intervals for TPMT activity derived from our study population. Of the 1000 individuals studied, six had a TPMT activity 52 nmol 6-MTG per g Hb per h (four women, two men) and were categorized as having de¢cient TPMT activity. There is a clear delineation between these patients and the next subtype population with low activity, which starts with a TPMT activity of 11nmol 6-MTG per g Hb per h. The homozygous status of de¢cient patients identi¢ed by our method has been con¢rmed by DNA analysis.
We have assumed that the frequency of individuals with de¢cient TPMT activity corresponds to a predicted heterozygote frequency of 14% and wildtype frequency of 85%. 3 Accordingly, the level between low and normal TPMT activity was set at 24 nmol 6-MTG per g Hb per h. In our prospective outpatient population study, 18 individuals can be considered to have high TPMT activity with levels of 455 nmol 6-MTG per g Hb per h.
Discussion
The awareness of the role of testing TPMT activity prior to starting thiopurine therapy is increasing, leading to greater clinical demand for the test. We recently published a non-extraction method for the determination of TPMT activity in RBC, with the emphasis placed on a rapid assay with fewer analytical steps, that has excellent imprecision characteristics. 7 Recognition of the importance of fast turn-around in order to minimize delay to patients' treatment lead us to make further modi¢cations to our method. As a result, the HPLC analysis was speeded up from a cycle time of 3.5 min to 2.5 min per sample. This, along with the automation of lysate haemoglobin measurement, has made it possible to analyse 60-90 samples a day on a single analytical platform. Choice of quality control materials is important for TPMT, and we have found that a frozen lysate (7708C) is ideal for this use. The measurement of lysate haemoglobin is an important source of variability in previous assays; the microassay used in this study shows excellent imprecision characteristics.
The prospective study of the TPMT activity in 1000 individuals has enabled us to de¢ne more fully the reference values for the assay with 6-thioguanine as substrate. This study found six individuals with undetectable TPMT activity, but with the size of population studied this is not statistically signi¢cantly di¡erent from the 1:300 suggested in previous work. 1, 3, 4 Using 6-thioguanine as a substrate, we found a range of TPMT activity values similar to that reported by Kroplin et al. 8, 9 (1.3-68 nmol 6-MTG per g Hb per h). The observation of a right tail to the wildtype distribution is of interest; this population therefore requires further investigation to elucidate the underlying basis. Our work presents a major prospective study of TPMT activity distribution. Previous studies have used relatively small numbers of samples to look at the distribution of TPMT activity, but ¢ndings have shown a distribution of TPMT similar to our study. 4, 11, 12 Another approach has been to analyse results from a national service for TPMT activity, 13 but there may be bias in such a population, with samples more likely to come from patients who have already had complications resulting from thiopurine therapy.
Measurement of TPMT activity prior to starting azathioprine or mercaptopurine therapy has a role in identifying the 1 in 300 patients who are at risk of severe myelosuppression when treated with standard doses of these drugs. In our study, individuals with de¢cient TPMT activity formed a subpopulation that was easy to distinguish, as they gave no detectable product (6-MTG) after a 60-min incubation. The high discriminating ability of this method for patients without enzyme activity can be attributed to the use of a non-solvent extraction preparation, standard and sample blank correction, the high sensitivity of £uorimetric detection and lack of interferences in the chromatogram.
